Share this article
Share this article
WALTHAM, Mass., March 1, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. This indication has been granted under accelerated approval based upon the HORIZON trial. PEPAXTO is the first anticancer peptide-drug conjugate approved in multiple myeloma.
Endeavour Silver Reports $19 9 Million Earnings in the Fourth Quarter, 2020 and $1 2 Million Earnings for the Full Year, 2020
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
ATS Provides Innovative Nuclear Decommissioning Solution to Holtec International
News provided by
Share this article
Share this article
CAMBRIDGE, ON, Feb. 12, 2021 /CNW/ - ATS Automation Tooling Systems Inc. (TSX: ATA) ( ATS or the Company ), an industry-leading automation solutions provider, today provided an update on its innovative nuclear decommissioning program for Holtec International, a diversified energy technology company and new ATS customer. The Order Booking was received in ATS third quarter of fiscal 2021 and is expected to be delivered over the next 9 months.
ATS scope of work includes the design, build and test of specialized tooling equipment to support the decommissioning of retired nuclear plants in Holtec s U.S. based fleet. The equipment is critical to the safe and efficient decommissioning of a nuclear power plant and will be tested underwater at ATS full-scale mock-up test facility. Included in the Order Booking is customer training in the use of the
Pexip delivers strong revenue growth and solid profitability in Q4 2020
Oslo, Norway, 11 February 2021 - The video communications provider, Pexip, today presented its quarterly results for the fourth quarter and full year 2020.
Pexip AS
Q4 2020
Pexip s subscription base measured in Annual Recurring Revenue (ARR) reached USD 81.9 million in Q4 2020, up from USD 47.2 million in Q4 2019, representing an increase of 73%. The growth was driven by a range of important customer wins both in the enterprise segment and in the public sector, such as a record deal with the US Defense Health Agency at approximately USD 2 million in ARR. At the same time the percent of retained revenue from existing customers, was 114% year-on-year, including churn of 10% year-on-year.
vimarsana © 2020. All Rights Reserved.